Got 90 seconds? Then listen to AdAlta’s managing director and CEO discuss the company’s recent progress with its lead drug candidate, AD-214.

AdAlta (ASX:1AD) is a drug company focused on the development of a treatment for idiopathic pulmonary fibrosis and other fibrotic diseases.

The company’s lead drug, AD-214, is based on antibodies or proteins that the immune system uses to kill off invaders or bacteria. In particular, the drug has antibodies that mimic those that keep sharks healthy.

The result is a range of unique compounds for use in treating serious diseases.

Stockhead gave AdAlta managing director and CEO Sam Cobb 90 seconds to update us on how AD-214 is progressing and what major milestones are around the corner.

Have a good idea for our next 90 Seconds With segment? Email us at [email protected].